Article info
PDFOriginal research
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis
- Correspondence to Dr Michael J Marmura, Department of Neurology, Thomas Jefferson University, Philadelphia, USA; Michael.marmura{at}jefferson.edu
Citation
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis
Publication history
- Received November 21, 2022
- Accepted April 19, 2023
- First published May 30, 2023.
Article Versions
- You are currently viewing a Previous version of this article (25 October 2023).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© American Society of Regional Anesthesia & Pain Medicine 2023. No commercial re-use. See rights and permissions. Published by BMJ.